News

Neurofilament Protein Is Promising Neurosarcoidosis Biomarker

A protein called neurofilament light chain (NFL), which supports nerve fibers, is elevated in adults with neurosarcoidosis — and appears to increase with more extensive brain inflammation — a study demonstrated. These findings support the neurofilament protein as a biomarker for disease activity in neurosarcoidosis, a form of…

Xentria Readies First Trial of XTMAB-16 for Sarcoidosis

The U.S. Food and Drug Administration (FDA) has approved beginning clinical trials testing XTMAB-16, Xentria’s investigational TNF-alpha inhibitor for the treatment of sarcoidosis. The first, a Phase 1 trial evaluating the therapy in healthy volunteers, is expected to start in July at the Parexel Baltimore Early Phase…

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…

FSR Awards $150K to Study Role of Microbes in Neurosarcoidosis

A researcher investigating pathogens — disease-causing microorganisms — capable of causing neurosarcoidosis has been awarded $150,000 from the Foundation for Sarcoidosis Research (FSR). The FSR Sarcoidosis Research Fellowship Grant will provide Paula Barreras, MD, of the Johns Hopkins University Hospital, with two years of funding for her project. Titled…

FSR’s Women of Color Committee Seeks Applicants

African American women diagnosed with sarcoidosis or who have strong connections to the sarcoidosis community, are invited to apply to become members of the Women of Color Committee of the Foundation for Sarcoidosis Research (FSR). The FRS Committee aims to provide insight into a large-scale education and awareness…